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Abstract
Objectives: To evaluate the association between AGEs and atherosclerotic lipid profiles among aging diabetic
patients in Taiwan.
Design and Methods: After age and gender matching, we selected 207 diabetic subjects and 174 diabetic
subjects with proteinuria. Lipid profiles, including total cholesterol (TC), triglycerides (TG), high density cholesterol-
lipoprotein (HDL-C) and low density lipoprotein-cholesterol (LDL-C) were measured using standard methods. AGEs
were measured with the immunoassay method.
Results: In general, males were heavier; however, females had higher AGEs, fasting glucose (GLU), TC, HDL-C and
LDL-C levels than males, and had higher TC/HDL-C, LDL-C/HDL-C, and TG/HDL-C ratios compared to males. AGEs
were more strongly correlated with TG levels and TCL/LDL-C, LDL-C/HDL-C and TG/HDL-C ratios when compared
to glucose or hemoglobin A1c. Subjects had higher AGEs levels (≧ 2.0 AU) with more adverse lipid profiles.
Conclusion: AGEs seem to be a good biomarker to evaluate the association between diabetes and atherosclerotic
disorders in aging diabetes.
Introduction
In the Framingham study, the mortality rate from cardi-
ovascular disease (CVD) was two times higher among
diabetic patients than the general population [1]. Simi-
larly, in the Multiple Risk Factor Intervention Trial
(MR-FIT), after an average of 12 years of follow up, the
risk of mortality from cardiovascular disease was much
higher among diabetic men than non-diabetic men,
especially with higher CVD risk factor levels [2].
Furthermore, in the Munich General Practitioner Pro-
ject, the major risk factors for macrovascular death
among diabetic patients during ten years of follow up
were age and glycosylated hemoglobin A1c levels [3].
Diabetes plays an important role in the development
and occurrence of cardiovascular disease. Previous stu-
dies have clearly demonstrated that diabetes mellitus is
one of the most important risk factors for atherosclero-
tic disorders; however, so far there is no good biological
marker that can predict atherosclerotic lesions among
diabetic patients. Diabetes may be associated with accel-
erated atherosclerosis by either increasing the conven-
tional risk factors, such as dyslipidemia and high blood
pressure, or diabetes-specific risk factors, such as
advanced glycation end products (AGEs), reactive oxy-
gen species (ROS) and matrix protein production [4].
Furthermore, the formation of AGEs may play a key
role in diabetes and CVD, leading to chronic hypergly-
cemia, dyslipidemia and oxidative stress [5].
AGEs are the product of the initial glycation chain
reaction in glucose metabolism [6,7]. In diabetes, hyper-
glycemia may be results in the cells unable to reduce
glucose intake, which then results in mitochondrial pro-
duction of reactive oxygen species and damaging of
DNA. This may lead to inactivation and accumulation
of the metabolites earlier in the metabolism pathway
which includes over-production of AGEs. AGEs are
reactive derivations of the Maillard process, from non-
enzymatic glucose-protein condensation reactions
between the glucose ketone groups and the amino
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groups of the protein, which may be associated with dia-
betes-related complications [8].
The purpose of this study is to evaluate the associa-
tion between AGEs and atherosclerotic profiles among
aging diabetic patients in Taiwan.
Materials and methods
Study subjects
All participating subjects were between 35 and 80 years
old, ethnically Han Chinese, with type 2 diabetes melli-
tus, and were recruited from the outpatient clinic of the
Tri-Service General Hospital in Taipei, Taiwan from
July 2007 to Dec. 2009. After age and gender matching,
we included 207 Type 2 diabetic patients without
nephropathies (DM) and 174 diabetic patients with
nephropathies (DN). All recruited patients fulfilled the
following criteria: (i) age between 35 to 80 years old; (ii)
fasting plasma glucose greater than 126 mg/dl; and (iii)
HbA1c greater than 6%. The study subjects were further
classified as DM or DN based on three surrogate end-
points: urinary albumin to creatinine ratio (ACR), BUN
and serum creatinine. ACRs were measured more than
twice at different time points. Patients who fulfilled any
one of the following three criteria were classified in the
DN group: (i) average ACR greater than 30 μg/mg; (ii)
serum creatinine greater than 1.7 mg/dl; (iii) BUN
greater than 20 mg/dl. The rest of the patients were
classified as the DM group. According to this definition,
micro- and macroalbuminuric patients were classified
into the DN group. Approval was obtained from the
Internal Review Board of Tri-Service General Hospital
before conducting the study, and an approved informed
consent form was signed by each subject.
Biochemical variable measurement
Atherosclerotic profiles, such as total cholesterol (TC),
triglycerides (TG), high-density lipoprotein cholesterol
(HDL-C) and low-density lipoprotein cholesterol (LDL-
C) levels were measured using standard methods. We
also calculated the TC/HDL-C, LDL-C/HDL-C and TG/
HDL-C ratios to represent the significance of the ather-
osclerosis. We further calculated the atherosclerotic
index (AI) based on the distribution of TC, TG, HDL-C
and LDL-C levels. For each subjects, we summed the
points from TC (TC ≤ 200 = 1 point, 200 < TC ≤ 240 =
2 points, TC > 240 = 3 points), TG, (TG ≤ 150 = 1
point, 150 < TG ≤ 200 = 2 points, TG > 200 = 3 points),
HDL-C (HDL-C ≥ 50 = 1 point, 50 > HDL-C ≥ 40 = 2
points, HDL-C < 40 = 3 points) and LDL-C (LDL-C ≤
130 = 1 point, 130 < LDL-C ≤ 160 = 2 points, LDL-C >
160 = 3 points); the higher AI may be represented the
more adverse atherosclerotic characteristics.
AGEs were measured using enzyme-linked immunoas-
say method (Hanson Hong Biomedical Co, Ltd, Taipei,
Taiwan), using a Hitachi 7150 (Osaka, Japan) analyzer,
and the within and between CV was 1.3% and 2.8%,
respectively.
Statistical analyses
All data were expressed as mean ± SD and the t-test
was conducted to evaluate the differences between two
groups. Spearman correlation coefficients were exam-
ined for fasting glucose (GLU), glycated hemoglobin
A1c (A1c) and AGEs in relation to these atherosclero-
tic profiles and parameters. Multi-variable regression
analyses were conducted to examine the association
between AGEs and atherosclerotic profiles after adjust-
ing for potential confounders, such as age and BMI,
and further adjusting for GLU and A1c. We further
evaluated the atherosclerotic characteristics of subjects
with AGEs greater than or equal to, or less than 2.0
AU.
All statistical analyses were conducted using the statis-
tical package SAS 8.2 (SAS institute Inc, Cary, NC,
USA).
Results
The general characteristics of study subjects by gender
are shown in Table 1. In general, females had higher
AGEs, A1C, TC, HDL-C and LDL-C levels than males
(p < 0.05). However, males had higher TC/HDL-C,
LDL-C/HDL-C, and TG/HDL-C ratios compared to
females (all p < 0.05).
Table 2 presents the Spearman correlation coefficients
of fasting glucose, A1c and AGEs levels on lipid profiles
and atherosclerotic characteristics among study subjects
according to gender and disease status. When compared
to GLU, A1c and AGEs, AGEs levels were more posi-
tively correlated with TG and TC/LDL-C, LDL-C/HDL-
C and TG/HDL-C ratios (especially in males) and nega-
tively correlated with HDL-C levels (all p < 0.01). These
characteristics were present in both DM and DN
subjects.
The multi-variable regression analyses of AGEs on
lipid profiles and atherosclerotic characteristics, after
adjusting for potential confounders, are presented in
Table 3. In Model III, after adjusting for age, BMI, GLU
and A1c levels, AGEs were positively associated with
TC, TG, TC/HDL-C, LDL-C/HDL-C, TG/HDL-C and
atherosclerotic index, and negatively associated with
HDL-C levels in both genders.
We further divided subjects into two subgroups based
on their AGEs levels (≧ 2.0 or < 2.0 AU). Table 4 shows
the lipid profiles and atherosclerotic characteristics for
different AGEs groups by gender. Subjects with AGEs ≧
2.0 AU had higher TC, TG, LDL-C levels (in females),
TC/HDL-C, LDL-C/HDL-C, TG/HDL-C ratios and
atherosclerotic indexes in both sexes.
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Discussion
In this study we examined different glucose metabolism
variables, such as fasting glucose (GLU), glycated hemo-
globin A1c (A1c) and AGEs. We found AGEs levels cor-
related positively with lipid profiles and atherosclerotic
characteristics, and this correlation was even better than
those for fasting glucose or A1c in both sexes. Even
after adjusting for age, BMI, GLU and/or A1c and other
potential confounders, AGEs are still significantly corre-
lated with lipid profiles and atherosclerotic
characteristics. More interestingly, the subjects with
higher AGEs levels had worse lipid profiles, more
adverse atherosclerotic characteristics and higher AI.
AGEs thus seem to be a good biomarker for evaluating
the association between diabetes and atherosclerotic dis-
orders among aging diabetic patients.
There are several interesting findings in this study, but
also some limitations. First, diet and physical activity
were not well controlled in this study. It may be asso-
ciated with non-differential misclassification which
Table 1 General characteristics of study subjects.
DM(N = 207) DN(N = 174)
Male(N = 81) Female(N = 126) Male(N = 71) Female(N = 103)
Mean ± S.D Mean ± S.D Mean ± S.D Mean ± S.D
Age(yr) 63.5 ± 8.7 62.4 ± 7.2y 66.3 ± 8.9 64.9 ± 6.8
Weight(kg) 69.9 ± 9.3*** 61.6 ± 10.0 70.0 ± 9.3*** 62.5 ± 9.7
BMI(kg/m2) 25.4 ± 2.9 25.3 ± 3.7 25.3 ± 3.2 26.2 ± 3.9
AGEs(AU) 1.7 ± 1.3 1.9 ± 1.3y 1.9 ± 1.5* 2.4 ± 1.5
Glucose(mg/dL) 143.0 ± 38.5 148.8 ± 42.2 152.1 ± 54.6 157.2 ± 57.4
HbAlc(%) 7.9 ± 1.4* 8.3 ± 1.4a 8.4 ± 1.7 8.8 ± 2.0
CHOL(mg/dL) 177.4 ± 32.7*** 195.3 ± 38.3 175.5 ± 44.4*** 203.0 ± 39.4
TG(mg/dL) 140.6 ± 75.5a 144.4 ± 63.1y 179.7 ± 125.0 189.0 ± 106.8
HDL-C(mg/dL) 45.9 ± 10.1*** 56.1 ± 13.2 43.2 ± 10.2*** 53.0 ± 13.0
LDL-C(mg/dL) 114.4 ± 30.4* 124.6 ± 34.7 116.1 ± 35.1* 129.8 ± 38.2
CHOL/HDL-C 4.0 ± 1.1* 3.7 ± 1.1y 4.3 ± 1.4 4.1 ± 1.2
LDL-C/HDL-C 2.6 ± 0.8 2.4 ± 0.9 2.8 ± 1.0 2.6 ± 0.9
TG/HDL-C 3.4 ± 2.3a 2.9 ± 1.8z 4.6 ± 3.6 4.0 ± 2.7
AI 6.2 ± 1.7 6.2 ± 1.9y 6.7 ± 1.9 6.9 ± 1.8
* p < 0.05, ** p < 0.01, *** p < 0.001 when compared by gender.
ap < 0.05bp < 0.01cp < 0.001 when compared with different statuses in males
xp < 0.05yp < 0.01zp < 0.001 when compared with different statuses in females
BMI: body mass index; AGEs: advanced glycation end products; HbA1c: hemoglobin A1c; CHOL: cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein-
cholesterol; LDL-C: low density lipoprotein-cholesterol; AI: atherosclerotic index
Table 2 Spearman correlation coefficient of fasting glucose, hemoglobin A1c (HbA1c) and advanced glycation end
products (AGEs) with lipid profiles.
DM(N = 207) DN(N = 174)
Males(N = 81) Females(N = 126) Males(N = 71) Females(N = 103)
Glucose HbA1c AGEs Glucose HbA1c AGEs Glucose HbA1c AGEs Glucose HbA1c AGEs
Age(yrs) -0.13 -0.15 -0.13 -0.12 -0.10 0.07 -0.40*** -0.10 -0.18 -0.01 0.03 -0.14
Weight(kg) 0.04 0.12 0.33** 0.23** 0.14 0.03 0.13 -0.08 0.27* -0.07 0.11 0.12
BMI(kg/m2) 0.11 0.18 0.23* 0.18* 0.13 0.08 0.15 -0.09 0.29* -0.08 0.05 0.11
CHOL(mg/dL) 0.10 0.21 0.12 0.34*** 0.34*** 0.34*** 0.10 0.12 0.35** 0.26** 0.17 0.15
TG(mg/dL) 0.08 0.10 0.77*** 0.12 0.24** 0.69*** 0.25* 0.32** 0.73*** 0.25* 0.26** 0.68***
HDL-C(mg/dL) -0.02 -0.13 -0.34** -0.07 0.03 -0.27** -0.13 -0.17 -0.35** 0.08 0.04 -0.36***
LDL-C(mg/dL) 0.12 0.18 0.12 0.34*** 0.35*** 0.27** 0.11 0.13 0.19 0.19 0.15 0.03
CHOL/HDL-C 0.10 0.20 0.44*** 0.30** 0.21* 0.51*** 0.15 0.13 0.48*** 0.10 0.09 0.41***
LDL-C/HDL-C 0.05 0.16 0.30* 0.32*** 0.27** 0.40*** 0.11 0.15 0.28* 0.13 0.14 0.26*
TG/HDL-C 0.11 0.11 0.73*** 0.12 0.18 0.65*** 0.26* 0.29* 0.72*** 0.09 0.14 0.63***
AI 0.18 0.15 0.56*** 0.29*** 0.33*** 0.51*** 0.20 0.27* 0.63*** 0.24* 0.22* 0.46***
*p < 0.05 **p < 0.01 ***p < 0.001
BMI: body mass index; AGEs: advanced glycation end products; HbA1c: hemoglobin A1c; CHOL: cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein-
cholesterol; LDL-C: low density lipoprotein-cholesterol; AI: atherosclerotic index
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could attenuate the results, but we still found significant
findings. Second, the duration and control of diabetes
was not considered and adjusted for in the final ana-
lyses, but we could estimate that the higher AGEs or
A1c, which may relate to poor control of diabetes and
then processed more significant atherosclerotic lesions.
However, the lipid profiles and atherosclerotic indexes
were indirect biomarkers for atherosclerosis; the gold
standard methods of diagnosis, such as coronary angio-
graphy angiography, should be considered to evaluate
coronary artery lesions in the future. Third, the cross-
sectional study design may limit our exploration. Long-
term follow-up study can provide more specific causal
relationships between AGEs and atherosclerotic diseases.
Finally, inflammation may be a potential confounder for
the relation between AGEs and atherosclerotic status;
but we did not measure inflammatory markers, such as
high sensitivity C-reactive protein, interleukin-6 and
tumor necrosis factors in this study. Further compre-
hensive study of biomarkers is indicated to identify the
potential mechanisms.
Many studies have shown that cardiovascular diseases
with rapid progression of atherosclerosis are the most
important causes of death in diabetes mellitus [4,9-11].
Other studies have shown that patients with diabetes
have high incidence of atherosclerotic diseases [2]. The
accelerated atherosclerosis in diabetic patients may be
explained by the hypothesis that human LDL-C oxida-
tion plays a role in the initiation of atherosclerosis
[11-13]. Duration and/or control of diabetes may relate
to later DM-induced complications, but it remains con-
troversial whether these include micro- or macro-vascu-
lar lesions [1,9]. However, most previous studies
suggested that A1c is one of the best indicators to eval-
uate diabetes control and predict the development of
diabetic-related complications [14]. In this study, we
found that AGEs were associated positively with total
cholesterol, TG, LDL-C and other atherosclerotic
indexes, and correlated negatively with HDL-C levels,
which suggests that AGEs may be a marker for athero-
sclerosis in diabetic patients. Furthermore, in this study,
these associations were even stronger than fasting glu-
cose or A1c levels. These findings indicate that not only
AGEs-modified forms of LDL-C but also AGEs-peptides
contribute to tissue injury and the development of
atherosclerosis in diabetic patients [11,12].
These findings were similar to other studies, which
indicate that AGEs might be associated with either dia-
betes control or diabetes-related complications. In addi-
tion, AGEs have been reported to be linked with the
effects of previous glycemic control and the subsequent
developments of micro- and macro-vascular complica-
tions in diabetes [6]. Furthermore, serum AGEs levels
are increased when patients have type 2 diabetes and
coronary artery disease (CAD) [15]. The association
between AGEs and diabetes-related complications may
not only due to hyperglycemia per se but also the pro-
ducts of AGEs. A study by Kanauchi and his colleagues
showed that AGEs may participate in the development
of CAD, even in non-diabetic participants [16]. How-
ever, other study showed that AGEs may significantly
impair LDL-receptor-mediated clearance which contri-
butes to the elevation of LDL-C levels in patients with
diabetes or renal insufficiency [12]. Furthermore, AGEs
may also contribute to the development of cardiovascu-
lar diseases through the modification of the lipid profiles
[12]..
AGEs are present in coronary atheroma of both dia-
betic and non-diabetic patients [17,18]. Concentrations
of circulating AGEs are correlated to the severity of cor-
onary artery disease and the adverse clinical outcomes
[19]. AGEs are linked to atherosclerosis in the following
potential mechanisms. First, AGEs promote protein
cross-linking, which leads to the covalent trapping of
pro-atherogenic particles such as LDL in the arterial
wall [11,20]. Second, excessive LDL trapping by hyper-
glycemia-induced AGEs may be associated with the
Table 3 Multivariable regression models for the
association between AGEs levels and atherosclerotic lipid
profiles with gender-specificaiton.
Model I Model II Model III
b(S.E) b(S.E) b(S.E)
Males
CHOL(mg/dL) 7.9(2.5)** 7.7(2.5)** 7.4(2.6)**
TG(mg/dL) 48.4(4.7)*** 48.6(4.8)*** 47.2(4.7)***
HDL-C(mg/dL) -2.7(0.6)*** -2.4(0.6)*** -2.3(0.6)***
LDL-C(mg/dL) 2.7(2.1) 2.3(2.1) 2.0(2.1)
CHOL/HDL-C 0.4(0.1)*** 0.4(0.1)*** 0.4(0.1)***
LDL-C/HDL-C 0.2(0.1)** 0.2(0.1)** 0.2(0.1)**
TG/HDL-C 1.4(0.1)*** 1.4(0.1)*** 1.3(0.1)***
AI 0.8(0.1)*** 0.8(0.1)*** 0.8(0.1)***
Females
CHOL(mg/dL) 8.3(1.9)*** 8.4(2.0)*** 7.6(1.9)***
TG(mg/dL) 41.8(3.4)*** 40.9(3.4)*** 40.0(3.4)***
HDL-C(mg/dL) -3.1(0.7)*** -3.0(0.7)*** -3.0(0.7)***
LDL-C(mg/dL) 4.9(1.8)** 5.1(1.9)** 4.3(1.8)*
CHOL/HDL-C 0.4(0.1)*** 0.4(0.1)*** 0.4(0.1)***
LDL-C/HDL-C 0.2(< 0.1)*** 0.2(< 0.1)*** 0.2(< 0.1)***
TG/HDL-C 1.1(0.1)*** 1.0(0.1)*** 1.0(0.1)***
AI 0.7(0.1)*** 0.7(0.1)*** 0.7(0.1)***
Model I: after adjusting for age(yrs)
Model II: after further adjusting for age(yrs) and BMI
Model III: after further adjusting for age(yrs), BMI, fasting glucose and HbA1c
*p < 0.05 **p < 0.01 ***p < 0.001
BMI: body mass index; AGEs: advanced glycation end products; HbA1c:
hemoglobin A1c; CHOL: cholesterol; TG: triglyceride; HDL-C: high-density
lipoprotein-cholesterol; LDL-C: low density lipoprotein-cholesterol; AI:
atherosclerotic index
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accelerated development of atherosclerosis in patients
with diabetes [11]. Third, AGEs may bind to apolipopro-
tein B particles which impaired their hepatic clearance,
induced retention of LDL in the aortic wall and
increased recognition by macrophages at this site, that
all associated with the increased localization of AGEs-
LDL in vessel wall and increased production of foam
cells and accelerating atheroma formation [18,21].
Lastly, AGEs may induce oxidant stress by enhancing
free radical generation from neutrophils. Furthermore,
AGEs might enhance neutrophil NADPH oxidase activ-
ity and contribute to the vascular oxidant stress and car-
diovascular disease in diabetic, uremic and elderly
patients [22]. As indicated in this study, AGEs may be
one of the better biomarkers to predict atherosclerosis
in diabetic patients.
We found that there was a different association
between AGEs and lipid profiles for males and females,
not only in patients with DM alone, but also in DM
patients with nephropathy. For example, after adjusting
for potential confounders, the association between AGEs
levels and atherosclerotic profiles was stronger in
females than males. This result was similar to other stu-
dies that reported AGEs levels were significantly asso-
ciated with mortality from all causes and coronary heart
disease mortality in women, but not in men [19]. The
associations between AGEs and lipid profiles were
different for the two sexes which suggested that AGEs
may play a role as a competing risk factor in athero-
sclerotic lesions when compared to other traditional
CVD risk factors. In females, AGEs are a relatively
important factor associated with lipid profiles, but in
males, other factors–such as cigarette smoking, alcohol
consumption and lower HDL-C–may be more closely
associated with atherosclerotic lesions and lipid profiles.
Otherwise, AGEs may represent an additional risk for
CVD only in relatively low-risk subjects [19].
More interestingly, there was a closer association
between AGEs and lipid profiles and atherosclerotic
index in patients with DM nephropathy than those with
DM alone. A possible explanation is that the patients
with DM nephropathy may have more serious illness
and higher AGEs levels, which may make them more
prone to develop DM-related atherosclerosis. However,
further studies are necessary to examine the pathophy-
siology and to understand the possible mechanisms.
Our results show the association between AGEs and
lipid profiles persisted even after adjusting for potential
confounders, and further adjusting for fasting glucose or
A1c levels, which suggested that there might evidence
to demonstrate that AGEs are potentially a better pre-
dictor of atherosclerotic lesions in diabetic patients than
fasting glucose or A1c. These findings were similar to
other studies asserting that AGEs may be associated
Table 4 General characteristics of study subjects by different AGEs levels.
AGE ≦ 2.0 (N = 193) AGE > 2.0 (N = 188)
Males(N = 88) Females(N = 105) Males(N = 64) Females(N = 124)
Mean ± S.D Mean ± S.D Mean ± S.D Mean ± S.D
Age(yrs) 65.6 ± 8.9 63.3 ± 7.4 63.8 ± 8.8 63.4 ± 6.9
Weight(kg) 67.9 ± 9.3***b 60.5 ± 9.8x 72.8 ± 8.5*** 63.3 ± 9.8
BMI(kg/m2) 24.8 ± 2.9b 25.2 ± 3.8x 26.3 ± 3.0 26.3 ± 3.8
Glucose(mg/dL) 147.0 ± 46.4 148.5 ± 47.5 147.5 ± 47.7 156.0 ± 51.3
HbAlc(%) 8.1 ± 1.6 8.3 ± 1.6x 8.1 ± 1.5* 8.8 ± 1.8
CHOL(mg/dL) 170.4 ± 36.5***a 189.2 ± 32.9z 185.3 ± 40.0** 206.9 ± 41.8
TG(mg/dL) 110.0 ± 64.0c 119.7 ± 56.8z 226.0 ± 109.4 202.2 ± 92.5
HDL-C(mg/dL) 47.5 ± 10.5***c 58.8 ± 12.9z 41.1 ± 8.6*** 51.5 ± 12.7
LDL-C(mg/dL) 113.6 ± 29.5 120.4 ± 30.6x 117.3 ± 36.4* 132.4 ± 39.7
CHOL/HDL-C 3.7 ± 1.2*c 3.3 ± 0.8z 4.7 ± 1.1* 4.3 ± 1.2
LDL-C/HDL-C 2.5 ± 1.0*b 2.2 ± 0.7z 3.0 ± 0.9 2.7 ± 1.0
TG/HDL-C 2.6 ± 1.8c 2.2 ± 1.2z 5.7 ± 3.4** 4.4 ± 2.5
AI 5.8 ± 1.4c 5.8 ± 1.5z 7.8 ± 1.7 7.4 ± 2.0
AI distribution n (%) n (%) n (%) n (%)
0-4 (n = 119) 46(46.5)*** 55(43.7)*** 3(5.7) 15(14.6)
5-8 (n = 190) 46(46.5) 59(46.8) 30(56.6) 55(53.4)
9-12 (n = 72) 7(7.1) 12(9.5) 20(37.7) 33(32.0)
* p < 0.05, ** p < 0.01, *** p < 0.001 when compared by gender.
ap < 0.05bp < 0.01cp < 0.001when compared with different statuses in males
xp < 0.05yp < 0.01zp < 0.001 when compared with different statuses in females
BMI: body mass index; AGEs: advanced glycation end products; HbA1c: hemoglobin A1c; CHOL: cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein-
cholesterol; LDL-C: low density lipoprotein-cholesterol; AI: atherosclerotic index
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with either control of diabetes or complications of dia-
betes, and also linked them with diabetes-related com-
plications such as atherosclerosis and restenosis after
percutaneous coronary intervention [23-25]
There is an age-dependent increase of serum AGEs
levels, especially after age 13 [26,27]. In this study, we
divided the patients into two subgroups based on their
AGEs levels (≥ 2 and < 2 AU). The AGEs ≥ 2 patients
were heavier, had larger BMIs and higher total choles-
terol and TG levels than patients with AGEs < 2. These
findings are similar to other studies showing that sub-
jects with higher AGEs had more adverse atherosclerotic
profiles than normal subjects [26].
We found that patients with higher AGEs had more
adverse atherosclerotic parameters and indexes, which
suggests that AGEs could be used as a marker to predict
atherosclerotic lesions. However, further studies are
necessary to evaluate the clinical relevance and clinical
application of AGEs testing, especially for the prevention
of diabetes-related atherosclerotic diseases.
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